

REPRINT FROM MARCH 26, 2015

PRODUCT R&D

RAISING THE COHBAR

By Lauren Martz, Staff Writer

A recently discovered mitochondrial peptide with metabolic effects on skeletal muscle suggests mitochondrial DNA may deserve a second look as a source of therapeutic targets. A group from [CohBar Inc.](#) and the [University of Southern California](#) found the peptide encoded in the mitochondrial genome, showed it mimics the effect of exercise and believes it could help treat Type II diabetes.

It's far from clear how many therapeutic targets might be encoded in mitochondrial DNA, although that has been the basis of CohBar's platform since it was founded in 2007. In January, the company completed an IPO that brought in \$11.25 million to help develop the discoveries within the company's labs.

Although the first therapeutic peptide from mitochondrial DNA — [humanin](#) — was discovered by CohBar's founders and other groups over a decade ago, no other new targets have been published until now. [Humanin](#) is secreted by mitochondria and protects cells from apoptosis and oxidative stress, and CohBar is developing the peptide and its analogs for Alzheimer's disease (AD) and other indications.

The discovery of [humanin](#) contradicted the long-standing idea that mitochondrial DNA contains only 37 genes, encoding 13 proteins, that act inside mitochondria. Those proteins are considered poor drug targets because delivering therapeutics across the multiple membranes that surround mitochondria is difficult.

In addition, [humanin's](#) discovery challenged the widespread belief that mitochondria — which create energy and regulate the response to oxidative stress — receive cellular signals but do not send signals to the rest of the cell.

"[Humanin](#) opened up the possibility that there might be additional biologically active peptides encoded in the mitochondria," said CohBar co-founder Pinchas Cohen. "We know that the mitochondria need to communicate with the rest of the cell and the rest of the body."

He added there could be as many as 80 unidentified short bioactive peptides encoded in the mitochondrial genome.

Cohen is dean of the USC Davis School of Gerontology and executive director of USC's Ethel Percy Andrus Gerontology Center.

"Humanin opened up the possibility that there might be additional biologically active peptides encoded in the mitochondria. We know that the mitochondria need to communicate with the rest of the cell and the rest of the body."

Pinchas Cohen, University of Southern California

Now, through its USC collaboration, CohBar has identified a second mitochondrial peptide, MOTS-c, that is secreted by mitochondria and shows activity in preclinical models of obesity and diabetes. (See "MOTS-c translation", page 6). Cohen told BioCentury the team has also found several other mitochondrial peptides that it has not yet disclosed, including a family of six small [humanin](#)-like peptides (SHLPs).

MITOCHONDRIAL MUSCLE

Cohen and colleagues identified MOTS-c by using a computational model to search for new short open reading frames within the mitochondrial genome that would represent proteins when translated using either the mitochondrial or standard genetic code. The compound is a 16-mer peptide encoded within the mitochondria's 12S rRNA.

But the unexpected finding was that the peptide could not be translated within the mitochondria by the organelle's translation machinery because the sequence contains mitochondrial stop codons. That meant the rRNA has to be transported out of the organelle for translation by the cytosolic machinery — in contrast to the 13 known mitochondrial proteins which are translated inside the organelles.

In humans and in mice, MOTS-c was present in circulating blood and skeletal muscle. To confirm the peptide was produced exclusively by mitochondria, the team depleted mitochondrial DNA from HeLa cells and found MOTS-c and its transcripts were eliminated.

MOTS-C TRANSLATION


A group from the University of Southern California has identified a new, short mitochondria-derived peptide, MOTS-c, that is encoded within the mitochondrial genome and promotes metabolic function.

MOTS-c is transcribed from the mitochondrial chromosome and originates from the 12S rRNA locus. The MOTS-c transcript is transported from the mitochondrion to the cytoplasm, where it can be translated into a 16-mer peptide. The MOTS-c transcript encodes mitochondrial stop codons, preventing translation inside the organelle.

Within the cell, MOTS-c inhibits the folate cycle and its downstream purine

synthesis pathway, resulting in AMPK activation. AMPK activation contributes to fatty acid oxidation, glucose uptake and insulin sensitivity. The USC team found the MOTS-c peptide in circulating plasma and skeletal muscle, suggesting it is secreted from the cell and acts at the muscle. MOTS-c stimulated glucose disposal and enhanced insulin sensitivity in skeletal muscles of mice. *Source: Based on an image from Lee, C., et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism (2015), with permission from CohBar Inc. and the USC authors.*

AMPK - AMP-activated protein kinase; MOTS-c - Mitochondrial open reading frame of the 12S rRNA-c



Next, the researchers looked for biological activity. In human embryonic kidney cells, MOTS-c or a synthetic analog increased expression of genes involved in cellular metabolism and inflammation. Specifically, MOTS-c activated AMPK-stimulated glucose clearance.

In mice fed a high-fat diet, MOTS-c prevented obesity without decreasing food intake and decreased hyperinsulinemia and hepatic lipid accumulation compared with vehicle. Moreover, daily treatment with MOTS-c increased respiratory exchange and glucose utilization in the skeletal muscles, resembling the effects of diet or exercise.

“We found that MOTS-c actually stimulated the same pathways in skeletal muscle that are stimulated by exercise in the animals,”

said Cohen. “We believe it mimics exercise’s effects. Mice fed a high-fat diet could continue to eat without gaining any weight.”

Finally, the team looked for age-related variations in peptide levels, because mutations and damage to mitochondrial genes over time can contribute to metabolic dysfunction and other diseases that occur with age. That is in part due to the fact that mitochondrial DNA lacks the same DNA repair mechanisms that protect nuclear DNA.

Cohen’s group found endogenous levels of MOTS-c were lower in aged mice than in younger mice. However, treatment of aged mice with MOTS-c restored insulin sensitivity to levels found in young mice.

“We believe it mimics exercise’s effects. Mice fed a high-fat diet could continue to eat without gaining any weight.”

Pinchas Cohen, University of Southern California

According to the researchers, the data suggest that restoring levels of MOTS-c could prevent or reverse age-related metabolic dysfunction and disorders.

Cohen told BioCentury the team is creating transgenic mice that overexpress MOTS-c to study the peptide’s effects on aging and disease. “We already know that the levels fall with aging and that conditions such as diabetes and obesity occur with aging, but we want to see if there is a specific loss of the peptide in metabolic diseases that can be corrected by treatment,” he said.

Results were published in *Cell Metabolism*. (See “Distillery”, page 17)

PEPTIDE PATH

Cohen believes MOTS-c has several advantages over the many other compounds in development for diabetes and obesity.

The first is that MOTS-c treatment would involve replenishing a naturally occurring peptide whose falling levels contribute to disease pathology.

Another advantage for MOTS-c, he said, is its mechanism of action. “Other drugs for diabetes and obesity work at various sites including the liver, pancreas, gut and brain. MOTS-c is a unique hormone because it acts primarily on muscle, which is an important site of glucose utilization.”

CohBar is the only company to disclose a platform for developing mitochondrial-derived peptides.

CEO Jon Stern told BioCentury the company has selected MOTS-c as its lead program and expects to conduct 12-18 months of IND-enabling studies before entering the clinic, but said the company hasn’t yet selected a lead indication.

The first order of business will be to develop more potent, longer-acting analogs of MOTS-c and test them in additional animal models, Stern said.

Stern added that the company is reserving some funds for new peptide discovery and for pursuing the SHLP family that was also identified by Cohen’s group.

Five of the six SHLP peptides promote cell survival and inhibit the effects of reactive oxygen species (ROS), which suggests those peptides could be active in metabolic or neurologic diseases. The sixth peptide has opposite effects — inducing apoptosis and inhibiting angiogenesis — and is being considered as a cancer therapeutic.

For now, CohBar is keeping its mitochondrial peptide assets in-house, but the company will consider partnerships for development in the future.

The [University of California Los Angeles](#) has filed patent applications covering the use of MOTS-c and its analogs in metabolic diseases. CohBar also has IP related to [humanin](#) analogs, the SHLP peptides and other undisclosed mitochondria-derived peptides. The university has exclusively licensed all IP related to mitochondria-derived peptides to CohBar.

COMPANIES AND INSTITUTIONS MENTIONED

CohBar Inc., Los Angeles, Calif.
University of California Los Angeles, Los Angeles, Calif.
University of Southern California, Los Angeles, Calif.

TARGETS AND COMPOUNDS

AMPK - AMP-activated protein kinase
Humanin (MT-RNR2) - Mitochondrially encoded 16S RNA
MOTS-c - Mitochondrial open reading frame of the 12S rRNA-c

REFERENCES

Lee, C., et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” *Cell Metabolism* (2015)

EDITORIAL & RESEARCH

NEWSROOM:

pressreleases@biocentury.com

SAN CARLOS, CA:

+1 650-595-5333; Fax: +1 650-595-5589

CHICAGO:

+1 312-755-0798; Fax: +1 650-595-5589

WASHINGTON, DC:

+1 202-462-9582; Fax: +1 202-667-2922

UNITED KINGDOM:

+44 (0)1865-512184; Fax: +1 650-595-5589

Editor: C. Simone Fishburn, Ph.D.

Associate Editor: Michael J. Haas

Senior Writers: Lauren Martz; Stephen Parmley, Ph.D.

Staff Writers: Selina Koch, Ph.D.; Mary Romeo;
Karen Tkach, Ph.D.; Mark Zipkin

Director of Research: Walter Yang

Copy Editor: Claire Quang

BioCentury®; Because Real Intelligence is Hard to Find™; BCIQ™; The BioCentury 100™; and The Clear Route to ROI™ are trademarks of BIOCENTURY PUBLICATIONS, INC. All contents Copyright © 2015, BIOCENTURY PUBLICATIONS, INC. ALL RIGHTS RESERVED. No part of BioCentury's Publications or Website may be copied, reproduced, retransmitted, disseminated, sold, distributed, published, broadcast, circulated, commercially exploited or used to create derivative works without the written consent of BioCentury. Information provided by BioCentury's Publications and Website is gathered from sources that BioCentury believes are reliable; however, BioCentury does not guarantee the accuracy, completeness, or timeliness of the information, nor does BioCentury make any warranties of any kind regarding the information. The contents of BioCentury's Publications and Website are not intended as investment, business, tax or legal advice, and BioCentury is not responsible for any investment, business, tax or legal opinions cited therein.

CORPORATE, SUBSCRIPTIONS & PRIVACY

BioCentury's mission is to provide value-added business information & analysis for life science companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.

BioCentury Publications, Inc.
BioCentury International Inc.

MAIN OFFICES

PO Box 1246
San Carlos CA 94070-1246
+1 650-595-5333; Fax: +1 650-595-5589

CORPORATE

Chairman: Karen Bernstein, Ph.D.

President & CEO: David Flores

Vice President/Commercial Operations: Thomas Carey

Vice President/Administration & CFO: Bennet Weintraub

Publisher: Eric Pierce

Executive Editor and Director, New Ventures:

Joshua L. Berlin

Senior Director/Commercial Operations:

Tim Tulloch

Senior Director/Operations: Julia Kulikova

Director/Business Intelligence: Chris Dokomajilar

Director/Multimedia Operations: Jeffrey Fitzgerald

Director/Multimedia Business Development:

Jamie Gould

Director/Digital Product Manager: Ravid Lazinsky,

Director/Marketing & Promotional Services:

Greg Monteforte

Director/Administration & Human Resources:

Susan Morgan

Production: Jenny Nichols

SUBSCRIBER SERVICES

Subscriber Services: subscribe@biocentury.com

Account Managers: Orlando Abello; Matt Krebs;
Michelle Ortega; Ron Rabinowitz

BUSINESS SERVICES

Accounting & Billing: finance@biocentury.com

Conferences: conferences@biocentury.com

Data Solutions Support:
support@biocentury.com

Privacy Policy: privacy@biocentury.com

Reprints/Permissions:

businessservices@biocentury.com

PRIVACY & ADVERTISING

In accordance with its Privacy Policy, BioCentury does NOT sell its customer information or usage data to third parties.

BioCentury does NOT sell advertising in the BioCentury, BioCentury Innovations or BioCentury Week in Review. BioCentury is pleased to acknowledge its conference partners and sponsors through unpaid promotional announcements in its publications. BioCentury MAY accept paid promotional messages from sponsors, which are displayed only on BioCentury's websites.